지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 399 - 408 (10page)
이용수
초록· 키워드
오류제보하기
Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney, have been shown to decrease the risk of heart failure hospitalization (HFH) across a range of patients with and without atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Following these CVOT results, SGLT2i (dapagliflozin, empagliflozin, sotagliflozin) also were reported to reduce HFH and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of existence or absence of T2DM. Ongoing studies have been conducted to evaluate the clinical benefit of SGLT2i (empagliflozin, dapagliflozin) in patients with heart failure with preserved ejection fraction (HFpEF). Although SGLT2i brought us to the entrance of a new era for prevention of HF incidence and worsening of HF, the search for pivotal mechanism of SGLT2i to improve our pharmacological armamentarium should continue in order to protect every HF patient from fatal progression of HF disease. In this review, we summarized the updated clinical evidences on SGLT2i (rather than basic and translational evidence) for reduction of HF risk in T2DM patients and favorable clinical outcomes in both HFrEF and HFpEF patients.
목차
등록된 정보가 없습니다.
참고문헌 (36)
참고문헌 신청
Wright EM / 2011 / Biology of human sodium glucose transporters / Physiol Rev 91:733~794
DeFronzo RA / 2021 / Pathophysiology of diabetic kidney disease : impact of SGLT2inhibitors / Nat Rev Nephrol
Zelniker TA / 2020 / Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2inhibitors : JACC state-of-the-art review / J Am Coll Cardiol 75:422~434
Alicic RZ / 2019 / Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease / Diabetes 68:248~257
Gilbert RE / 2015 / Heart failure in diabetes : effects of anti-hyperglycaemic drug therapy / Lancet 385:2107~2117
DeFronzo RA / 2021 / Pathophysiology of diabetic kidney disease : impact of SGLT2inhibitors / Nat Rev Nephrol
Zelniker TA / 2020 / Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2inhibitors : JACC state-of-the-art review / J Am Coll Cardiol 75:422~434
Alicic RZ / 2019 / Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease / Diabetes 68:248~257
Gilbert RE / 2015 / Heart failure in diabetes : effects of anti-hyperglycaemic drug therapy / Lancet 385:2107~2117
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
새로운 심부전 약제, SGLT2 억제제
대한내과학회지
2023 .04
-
당뇨병을 동반하지 않는 심부전 환자에서 SGLT2 Inhibitor의 심장기능에 대한 효과
병원약사회지
2024 .08
-
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .09
-
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Korean Circulation Journal
2019 .01
-
Use of dapagliflozin in patients with advanced diabetic kidney disease
Kidney Research and Clinical Practice
2018 .01
-
Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
Korean Circulation Journal
2020 .01
-
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
Diabetes and Metabolism Journal
2022 .09
-
제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과
대한내과학회지
2020 .08
-
Metformin에 추가로 병용되는 SGLT2 inhibitors의 효능과 안전성에 관한 고찰
한국임상약학회지
2018 .01
-
Are sodium-glucose co-transporter-2 inhibitors associated with improved outcomes in diabetic patients admitted to intensive care units with septic shock?
Acute and Critical Care
2024 .05
-
Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
Korean Circulation Journal
2019 .01
-
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
Korean Circulation Journal
2020 .01
-
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement
Kidney Research and Clinical Practice
2020 .01
-
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2022 .07
-
SGLT2 억제제와 만성 콩팥병
대한내과학회지
2024 .04
-
Superior heart failure protecting effect of selective SGLT2 inhibitor than non-selective SGLT1,2 inhibitor in the diabetic heart failure zebrafish model
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Diabetes and Metabolism Journal
2020 .01
-
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Diabetes and Metabolism Journal
2021 .01
-
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
Journal of Obesity & Metabolic Syndrome
2019 .01
-
Diabetes Management in Patients with Heart Failure
Diabetes and Metabolism Journal
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0